START Strengthens Its Global Network with CURC Acquisition
START's Site Network Enhances Leadership in Urological Cancer Trials
The START Center for Cancer Research ("START"), a prominent authority in early-phase oncology clinical trials, has recently expanded its global network by acquiring Carolina Urologic Research Center ("CURC"), a leading site specializing in genitourinary (GU) oncology. This strategic move is aimed at bolstering START's capabilities in one of the most rapidly evolving areas of cancer research. GU cancers are increasingly prevalent, with an estimated 2.6 million new cases diagnosed annually, accounting for more than one in eight cancer diagnoses worldwide.
Integration of Specialized Capabilities
Founded in 1998 by Dr. Neal Shore, MD, FACS, CURC has played a pivotal role in conducting nearly 500 clinical trials, solidifying its status as the premier urologic oncology site globally in both volume and quality. CURC’s established expertise in both early- and late-phase trials equips START with valuable scientific insights and leadership for its extensive research portfolio.
A Dedicated Center of Excellence
In conjunction with the integration of CURC, START is establishing a dedicated Center of Excellence (COE) that will focus on providing comprehensive trial solutions for urological cancers. This COE is designed to bridge the existing gap between research innovations and clinical applications by integrating both early and late-phase trial executions with direct patient-to-PDX translational services, ultimately enhancing the research-to-treatment continuum.
Impact on Urological Cancer Research
Dr. Neal Shore will lead the COE in driving innovation within the realm of urologic oncology. This initiative will amplify START’s partnerships with top-tier urological practices globally, ensuring sponsors have access to a fully integrated, end-to-end solution that expedites the development and delivery of breakthrough therapies to patients.
Nick Slack, MBE, Chairman and CEO of START, emphasizes the significance of this expansion, stating, "Urologic cancers are among the fastest-growing sectors in oncology, driven by different factors such as an aging population, rising incidence rates, and improvements in diagnostic methods. We are committed to facilitating research opportunities that allow patients to access the most advanced therapeutic options available today. CURC’s exceptional standing, strong sponsor relations, and deep insights will greatly enhance our integration and growth within this vital area.”
Commitment to Patient-Centric Innovations
Dr. Neal Shore, Founder and Medical Director of CURC, expressed enthusiasm about joining the START network: "This partnership marks an exciting evolution for CURC. As a leader in early-phase oncology trials, START shares our dedication to delivering the benefits of clinical trials to patients across the globe. By becoming part of the START network, we will gain access to enhanced expertise and resources, effectively expanding our influence on urologic oncology research. Together, we strive to create greater opportunities for patients, sponsors, and investigators alike.”
About START
START is firmly established within community oncology centers worldwide, providing unique access to specialized preclinical and early-phase clinical trials of innovative anti-cancer agents. With over a thousand early-phase trials conducted, including numerous therapies that have received FDA or EMA approval, START boasts the most extensive roster of Principal Investigators (PIs) across its eight clinical trial sites. It is profoundly dedicated to facilitating the transition from trials to treatments, fulfilling the hopes of patients, families, and healthcare professionals globally.
About Carolina Urologic Research Center
Carolina Urologic Research Center (CURC) is well-regarded both nationally and internationally as a top-tier clinical research site within the United States. CURC employs a highly skilled team of healthcare professionals, which includes 6 board-certified urologists and 22 experienced research staff, allowing it to participate in approximately 500 national and international clinical research trials dedicated to various urologic conditions over the last 25 years.
Frequently Asked Questions
What is the significance of START's acquisition of CURC?
This acquisition enhances START's capabilities in urological cancer research, providing greater access to expertise, resources, and clinical trial solutions.
How many clinical trials has CURC conducted?
CURC has been involved in nearly 500 clinical trials, making it a leading site in urologic oncology globally.
What will the Center of Excellence focus on?
The Center of Excellence will specialize in urological cancers, integrating trial solutions and accelerating the development of novel therapies for patients.
Who leads the Center of Excellence?
Dr. Neal Shore, the founder of CURC, will lead the Center of Excellence and drive the initiative to enhance innovation in urologic oncology.
What does START aim to achieve through this expansion?
START aims to lead research in urological cancers, ensuring patients have access to advanced therapeutic options while continuing to innovate in clinical trial methodologies.
